E-Paper
India's Serum Institute resumes Covishield production as Covid cases surge
SII CEO Adar Poonawalla says Covishield manufacturing has resumed, 6M Covovax booster doses ready, and manufacturers are ready but no demand yet.
Serum Institute of India (SII) CEO Adar Poonawalla on Wednesday said it has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection.
He said the company already has six million booster doses of Covovax vaccine available and adults must take the booster shot.
Reacting to reports of COVID-19 vaccines shortage, he said manufacturers are ready but there has been no demand.
Also Read: India records 7,830 new Covid cases, active infections breach 40,000-mark
"Just as a precaution, at risk we have done it so that people have a Covishield as a choice if they want it," Poonawalla told PTI on restarting of manufacturing of the vaccine.
The company had stopped manufacturing of Covishield in December 2021.
Also Read: Covovax to be available on CoWIN as booster dose soon. Check details
On Covovax which has been approved as a booster dose for 18-years and above, he said, "We have six million doses ready but the demand is exactly zero."
Covovax booster is now on the CoWin app, he said.
